The challenge of PERSISTENT FACIAL ERYTHEMA (PFE) is
There’s what patients see and what you should target
Actual PFE patient
Explore the benefitsThe challenge of PERSISTENT FACIAL ERYTHEMA (PFE) is
There’s what patients see and what you should target
Actual PFE patient
Explore the benefitsPFE in rosacea—which does not respond to treatments for papules and pustules—is primarily caused by chronic vascular dysregulation. Vasodilation increases cutaneous blood flow at affected sites, leading to facial erythema that may become permanent over time if left untreated.3
RHOFADE is the first and only alpha1A-adrenoceptor agonist approved to treat PFE in rosacea, causing constriction of smooth muscle in blood vessel walls to help prevent progression and reduce PFE. RHOFADE provides an opportunity to address chronic vascular dysregulation and target PFE at the source.2,4
RHOFADE delivers rapid reductions in redness of PFE, with visible improvement seen in as little as 1 hour on the first day of treatment.* Through 52 weeks of treatment, RHOFADE provided continual reductions in redness—with nearly half of patients seeing a ≥1-grade improvement at week 52 before daily application.5-8,†
RHOFADE cream offers consistent tolerability with a low incidence of adverse events. Once-daily RHOFADE for 52 weeks resulted in fewer adverse events and a high degree of dermal tolerability.6
ELIGIBLE PATIENTS MAY PAY AS LITTLE AS $0 FOR THEIR RHOFADE PRESCRIPTION‡
CEA: Clinician Erythema Assessment; PFE: persistent facial erythema; SSA: Subject Self-Assessment.
The REVEAL Trial: The primary efficacy endpoint was defined as the proportion of patients with a ≥2-grade reduction in erythema from baseline on both the CEA and SSA scales measured at hours 3, 6, 9, and 12 on day 29.4
A RHOFADE response was defined as a composite ≥1-grade improvement in erythema on the CEA and SSA scales at any time point after the dose on day 1 or at any time point during a study visit at weeks 4, 26, or 52.8
Per prescription for patients with commercial insurance who have met their deductible and have a plan that covers RHOFADE cream.
INDICATION: RHOFADE® (oxymetazoline HCl) Cream, 1% is indicated for the topical treatment of persistent facial erythema associated with rosacea in adults. ADVERSE EVENTS: In the pivotal trials, the most common adverse reactions (≥1%) were: application-site dermatitis (2%), pruritus, erythema and pain (all 1%), and worsening inflammatory lesions of rosacea (1%).
Please see Full Prescribing Information.
You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
INDICATION: RHOFADE® (oxymetazoline HCl) Cream, 1% is indicated for the topical treatment of persistent facial erythema associated with rosacea in adults. ADVERSE EVENTS: In the pivotal trials, the most common adverse reactions (≥1%) were: application-site dermatitis (2%), pruritus, erythema and pain (all 1%), and worsening inflammatory lesions of rosacea (1%).
Please see Full Prescribing Information.
You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.